Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Core claim (from the paper): protein tyrosine phosphatases (PTPs) are cancer-relevant nodes, and small-molecule inhibitors (esp. aimed at PTP1B, SHP2, Cdc25, PRL) are argued to be plausible targeted therapies based on biochemical/structural and early in-cell evidence.



     Long Explanation


    Paper Review (BGPT): Targeting PTPs with small molecule inhibitors in cancer treatment
    Publication: 2008-02-08 β€’ DOI: 10.1007/s10555-008-9113-3

    1) Visual Knowledge Skeleton (what the paper is doing)

    2) Paper Metadata & Positioning (from provided extraction)

    The plotted values (incoming citations, reference count, excerpts) come from the user-provided BGPT extraction record for DOI 10.1007/s10555-008-9113-3.

    3) Mechanistic claims the paper makes (and what evidence type they correspond to)

    A. Cancer signaling logic β†’ PTPs as drug targets
    The paper argues that PTPs regulate tyrosine phosphorylation and that imbalance between kinases and phosphatases is linked to cancer; thus PTPs are potential drug targets and may have β€œunique modes of action” relative to kinase inhibition.
    B. Target selection: PTP1B, SHP2, Cdc25, PRL
    The review highlights these PTP families and summarizes evidence that they are implicated in oncogenesis/tumor progression (including, for PRL, a metastasis association and structural claims about PRL1 trimerization).
    C. Chemistry/Drug-design logic: selectivity via bidentate or peripheral-site engagement
    A key barrier the paper stresses is the conserved nature of PTP active sites, motivating inhibitor designs that engage additional, less-conserved regions (e.g., β€œbidentate ligands” using a pTyr surrogate and an adjacent peripheral site), plus reliance on structural information from inhibitor complexes.

    4) Evidence-strength critique (skeptical review)

    What is known vs assumed in this review
    • Known (from the review’s described evidence types): the paper summarizes biochemical/structural and some cell-based activities for example inhibitors and highlights mechanisms such as SHP2 autoinhibition release and PRL1 trimerization.
    • Assumed / extrapolated (review-level gaps): because this is a narrative review (not a new experimental study), it is inherently limited in how directly it can quantify clinical translational success of PTP inhibition. The strongest translational test would be consistent in vivo pharmacology-to-tumor-outcome linkage with clear target engagement and selectivity, but the review mainly compiles evidence across different PTPs, inhibitor chemotypes, and model systems.
    Drug-targeting blind spots (what could break the logic)
    • Selectivity vs conserved chemistry: the review explicitly notes active-site conservation, but a critical unresolved risk is that β€œpotency” against one PTP may still translate into off-target PTP engagement, potentially confounding phenotype attribution.
    • Target engagement uncertainty: many small-molecule PTP inhibitors are reversible/irreversible and sometimes use electrophilic/covalent chemistries (not fully enumerated as a general class in this specific review text block). Without consistent biochemical confirmation of pathway-level target engagement in tumor contexts, phenotype attribution can remain ambiguous.

    5) Cross-check using additional provided primary literature (optional triangulation)

    The provided dataset includes examples of more primary work on small-molecule PTP inhibition in cancer-like contexts, which can help triangulate whether selectivity and mechanistic binding have become more rigorous over time.
    Triangulation example: VHR multidentate PTP inhibitors (cervix cancer cells)
    A 2009 primary medicinal chemistry study reports competitive inhibition of VHR by a lead multidentate inhibitor (Ki β‰ˆ 0.81 Β΅M) with co-crystal structure data (PDB 3F81) and antiproliferative effects in HeLa/CaSki at 20 Β΅M, while not inducing apoptosis under the stated conditions.

    6) What would disprove the review’s therapeutic optimism?

    • If future work demonstrates that clinically relevant PTP inhibition fails to produce consistent tumor-growth effects after target engagement is verified, then the β€œunique modes of action” expectation would be weakened.
    • If off-target PTP engagement (due to conserved catalytic features) systematically drives the observed phenotypes, then PTP-centric mechanistic conclusions would be confounded.


    Feedback:    

    Updated: April 15, 2026

     BGPT Paper Review


    Study Novelty

    40%

    As a 2008 narrative review, novelty is limited: it organizes known biological rationale for PTPs and summarizes then-current inhibitor-design strategies (notably active-site selectivity challenges and example inhibitor scaffolds) rather than introducing new methods or datasets in the paper itself.


    Scientific Quality

    60%

    Quality is moderate for a review: it is structured, discusses mechanism and chemistry challenges (especially selectivity due to conserved active sites), and covers multiple PTP targets. Main red-flag is that causal translation to clinical efficacy is not established within a single unified experimental framework, and the review format cannot resolve target-engagement/off-target confounds.


    Study Generality

    70%

    The review is fairly general across cancer-relevant PTP targets and inhibitor design logic (selectivity strategies, structural information usage), but it focuses on a limited target subset (PTP1B, SHP2, Cdc25, PRL), reducing cross-PTP generality.


    Study Usefulness

    70%

    Useful as an educational/strategic overview of PTP drug discovery challenges (selectivity) and target-specific motivations. Less useful for decision-making without a modern, quantitative comparative meta-analysis or direct clinical outcome data in the review.


    Study Reproducibility

    40%

    As a narrative review, the paper’s reproducibility depends on re-reading and re-implementing the underlying cited studies; it does not provide new experimental protocols, datasets, or full methodological details for any single primary experiment.


    Explanatory Depth

    60%

    Mechanistic explanations for why PTPs might promote or inhibit cancer signaling are provided (e.g., PTP1B/SHP2/Cdc25/PRL logic; SHP2 autoinhibition release; PRL1 trimerization concept). However, depth is review-level and not a fully integrated system-level mechanistic causal model, limiting β€œend-to-end” explanatory power.


    🎁 Authors: Collect 56 Free Science Tokens (β‰ˆ $5.6 USD)

    Claim My Author Tokens

    Use for 14 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $5.6 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Extract PTP targets (PTP1B, SHP2, Cdc25, PRL) from the review text, build a bipartite graph of targets↔inhibitor design strategies, and rank evidence types by mechanistic linkage using the provided extraction fields.



     Hypothesis Graveyard


    The β€œPTPs will universally behave as kinase-antagonist tumor suppressors” framing is over-simplified: the review itself describes PTPs acting as positive signaling contributors (e.g., SHP2 and PTPΞ± contexts), so any universal antagonist model is likely false across PTPs and contexts.


    β€œSelectivity is mainly solved by bidentate design” may be insufficient: even with bidentate strategies, cross-PTP off-targets can persist because many peripheral-site features and inhibitor physicochemical properties may still overlap; selectivity must be empirically demonstrated with broad panels and functional readouts.

     Science Art


    Paper Review: Targeting PTPs with small molecule inhibitors in cancer treatment Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending